LeMaitre Vascular’s (LMAT) Buy Rating Reiterated at Roth Mkm

Roth Mkm reaffirmed their buy rating on shares of LeMaitre Vascular (NASDAQ:LMAT) in a research report released on Thursday morning,Benzinga reports. They currently have a $117.00 target price on the medical instruments supplier’s stock, up from their prior target price of $108.00.

Other equities analysts also recently issued research reports about the company. Wall Street Zen raised LeMaitre Vascular from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Citizens Jmp upped their price objective on LeMaitre Vascular from $113.00 to $118.00 and gave the company a “market outperform” rating in a report on Thursday. Barrington Research reissued an “outperform” rating and set a $95.00 target price on shares of LeMaitre Vascular in a report on Friday, February 20th. Cantor Fitzgerald reissued a “neutral” rating and issued a $95.00 target price on shares of LeMaitre Vascular in a research report on Monday, November 10th. Finally, Weiss Ratings lowered shares of LeMaitre Vascular from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Tuesday. Three analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company. According to MarketBeat.com, LeMaitre Vascular currently has a consensus rating of “Hold” and an average price target of $105.80.

LeMaitre Vascular Price Performance

Shares of LMAT opened at $108.18 on Thursday. The company’s 50-day moving average is $87.02 and its 200-day moving average is $88.36. The company has a debt-to-equity ratio of 0.44, a current ratio of 13.58 and a quick ratio of 11.45. The firm has a market capitalization of $2.45 billion, a PE ratio of 43.10, a PEG ratio of 2.19 and a beta of 0.72. LeMaitre Vascular has a fifty-two week low of $71.42 and a fifty-two week high of $115.33.

LeMaitre Vascular (NASDAQ:LMAT) last announced its earnings results on Wednesday, February 25th. The medical instruments supplier reported $0.68 EPS for the quarter, topping the consensus estimate of $0.67 by $0.01. The business had revenue of $64.45 million during the quarter, compared to the consensus estimate of $62.98 million. LeMaitre Vascular had a net margin of 23.13% and a return on equity of 15.02%. LeMaitre Vascular’s revenue was up 15.7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.49 EPS. LeMaitre Vascular has set its FY 2026 guidance at 2.810-3.010 EPS and its Q1 2026 guidance at 0.640-0.690 EPS. Equities analysts forecast that LeMaitre Vascular will post 1.94 EPS for the current year.

LeMaitre Vascular Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 26th. Stockholders of record on Thursday, March 12th will be issued a dividend of $0.25 per share. This is an increase from LeMaitre Vascular’s previous quarterly dividend of $0.20. The ex-dividend date of this dividend is Thursday, March 12th. This represents a $1.00 annualized dividend and a dividend yield of 0.9%. LeMaitre Vascular’s payout ratio is currently 31.87%.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of LMAT. Parkside Financial Bank & Trust lifted its position in LeMaitre Vascular by 1,913.3% during the second quarter. Parkside Financial Bank & Trust now owns 302 shares of the medical instruments supplier’s stock worth $25,000 after purchasing an additional 287 shares during the period. Cornerstone Planning Group LLC raised its position in shares of LeMaitre Vascular by 534.0% in the 3rd quarter. Cornerstone Planning Group LLC now owns 336 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 283 shares in the last quarter. MAI Capital Management bought a new stake in shares of LeMaitre Vascular during the 3rd quarter worth approximately $38,000. First Horizon Corp acquired a new stake in shares of LeMaitre Vascular during the 3rd quarter worth approximately $39,000. Finally, Geneos Wealth Management Inc. boosted its position in shares of LeMaitre Vascular by 250.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 557 shares of the medical instruments supplier’s stock worth $47,000 after acquiring an additional 398 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company’s stock.

Trending Headlines about LeMaitre Vascular

Here are the key news stories impacting LeMaitre Vascular this week:

• Positive Sentiment: Q4 results beat and above‑consensus guidance: LeMaitre reported $0.68 EPS vs. $0.67 consensus and revenue of $64.45M (vs. $62.98M est.); management raised Q1 and FY2026 EPS and revenue guidance, signaling continued top‑line momentum. Press Release
• Positive Sentiment: Dividend increase: Company raised the quarterly dividend 25% to $0.25/share (ex‑dividend March 12), returning cash to shareholders and supporting income‑oriented demand.
• Positive Sentiment: Analyst bullishness: Multiple firms raised ratings/targets — Citizens JMP to $118 (market outperform) and Roth MKM reaffirmed Buy and raised target to $117 — these are constructive for sentiment. Analyst Note
• Neutral Sentiment: Investor outreach: Management will participate in five investor conferences in March, increasing visibility and allowing direct Q&A with investors. Conference Notice
• Neutral Sentiment: Earnings call coverage and transcripts are available for deeper color on drivers (procedure volumes, product mix, backlog) for investors doing fundamental diligence. Earnings Transcript
• Negative Sentiment: Mixed analyst targets; some firms still imply downside: Wells Fargo raised its target but keeps an “equal weight” rating with a $94 target (below current price), and a few targets remain lower than the stock’s recent level — this can trigger profit‑taking or short‑term selling. Analyst Notes

LeMaitre Vascular Company Profile

LeMaitre Vascular, Inc is a specialty medical device company focused on the development, manufacture and marketing of products for the treatment of peripheral vascular disease. Headquartered in Burlington, Massachusetts, the company’s offerings include a broad portfolio of vascular surgical instruments, grafts, patches, catheters and embolic protection devices. LeMaitre’s product lines address key areas such as arterial reconstruction, endovascular repair and vascular access, serving the needs of cardiovascular surgeons and interventional specialists.

Founded in 1983 by George D.